Overview

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Status:
Completed
Trial end date:
2018-04-16
Target enrollment:
Participant gender:
Summary
To validate the superiority of Gemcitabine/Cisplatin/S-1 over Gemcitabine/Cisplatin for unresectable biliary tract cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Kansai Hepatobiliary Oncology Group
Treatments:
Cisplatin
Gemcitabine
S 1 (combination)
Tegafur